Abstract: The present invention relates to methods and compositions for treating cattle to modulate the abundance of Fusobacterium varium in the gastrointestinal tract with the intent to reduce liver abscess occurrence or severity, or to improve cattle growth or feed efficiency.

Abstract: The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases.

Abstract: The present invention relies on the discovery that, surprisingly, when it is produced locally in the epidermis, hepcidin is able to directly initiate the recruitment of neutrophils by increasing the CXCL1 production in keratinocytes. While hepcidin had no direct antimicrobial activity against Group A Streptococcus (GAS), injection of hepcidin, at the site of infection prevented GAS systemic spread. Hepcidin agonists may represent a novel therapeutic to prevent life threatening bacteremia not only in streptococcal NF but also in complicated infections due to compromised host immunity. The present invention relates to a method for treating Gram-positive bacterial infection in a patient in need thereof, comprising administering to the patient hepcidin polypeptide. More specifically, it concerns method for treating with mature form of hepcidin, gram-positive bacterial infection such as Group A Streptococcus infection which could be associated with Necrotizing fasciitis (NF).

Abstract: The present invention relates to a composition and method for inhibiting the growth of pathogens causing liver abscesses in bovines. The composition comprises of one or more broad host-range (polyvalent) bacteriophages capable of infecting and lysing or more Fusobacterium species and an acceptable carrier for delivering said composition to said bovine. The bacteriophages are isolated and characterized for infecting and inhibiting the growth of pathogens. Particularly, the composition is orally administered daily to bovines. Moreover, the present invention relates to the method for controlling and inhibiting the growth of pathogens causing liver abscesses in bovines comprising sampling of cattle rumen; preparation of phage pools; isolation of polyvalent F. necrophorum phages; quantification of Fusobacterium species level in cattle rumen; creation of a Fusobacterium strain library; and genome sequencing of Fusobacterium species.

Abstract: Cyclodextrin compound therapeutics to reduce age-related non-bisretinoid lipofuscin in a patient having a buildup of same, said method comprising administering 2-hydroxypropyl-?-cyclodextrin, or its derivatives, or ?-cyclodextrin or its derivatives, or ?-cyclodextrin or its derivatives, or ?-cyclodextrin or its derivatives in an amount effective to reduce non-bisretinoid lipofuscin levels. The methods include treating and/or preventing aging of the skin, muscle and other tissues and organs, which may result in increased life-span or health-span.

Abstract: The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases.

Abstract: In some embodiments, the present disclosure pertains to methods of monitoring dioxane biodegradation in an environment by: (1) exposing a sample from the environment to an oligonucleotide probe that targets at least one bacterial nucleotide sequence; (2) detecting the presence of the at least one bacterial nucleotide sequence in the sample from the environment; and (3) correlating the presence of the at least one bacterial nucleotide sequence to dioxane biodegradation in the environment. In some embodiments, the methods of the present disclosure can be used to determine whether monitored natural attenuation (MNA) of dioxane will occur in the environment. In some embodiments, the methods of the present disclosure can be used to determine whether dioxane decontamination is needed. Additional embodiments of the present disclosure pertain to oligonucleotide probes for monitoring dioxane biodegradation in an environment.

Abstract: A process for manufacturing vital wheat gluten with substantially no objectionable flavor or aroma includes extracting gluten from wheat or wheat flour in an aqueous process to provide vital wet gum wheat gluten which is then mixed with an aqueous preparation containing an amount of antioxidant effective to prevent production of an objectionable flavor or aroma in a subsequent drying step. The aqueous antioxidant/gluten mixture is dried to produce dried vital wheat gluten with substantially no objectionable flavor or aroma.

Abstract: New 2-amino-4-morpholino-6-propyl-1,3,5-triazines having the formula ##STR1## wherein R.sub.1 is hydrogen, alkyl, aralkyl or acetyl,R.sub.2 is hydroxyl, hydroxyalkyl, alkoxyalkyl, dialkylamino, arylhydroxyalkyl, (hydroxy-cycloalkyl)alkyl, alkanoyloxyalkyl, benzoyloxyalkyl, phenylacetyloxyalkyl, aminocarbonyloxyalkyl, COR.sub.3 or CONR.sub.4 R.sub.5, orNR.sub.1 R.sub.2 =(hydroxyalkyl)alkyleneimino,R.sub.3 =alkyl, aryl, haloaryl, alkylaryl, alkoxyaryl, aralkyl or aryloxy,R.sub.4 =R.sub.5 =hydrogen or alkyl, alkyl, alkoxy and alkanoyloxy having 1 to 4 carbon atoms, cycloalkyl and alkyleneimino having 4 to 6 carbon atoms. Moreover, when R.sub.1 is acetyl, R.sub.2 is acetoxyalkyl.Processes for the preparation thereof and pharmaceutical compositions containing the same are also given. In particular, these compounds are useful for the treatment of cognitive and behavioral disorders associated with aging and dementia syndromes, e.g. those associated with Alzheimer's disease.